Background
• To describe patients' treatment satisfaction, perceived necessity, perceived concern and adherence with current DMT • To explore the factors that influence the likelihood of DMT adherence
Objective
• Adherence to disease modifying therapy (DMT) is necessary to achieve optimal clinical benefit; 1 however, adherence is suboptimal in multiple sclerosis (MS) patients with rates from 41 to 88 percent. 2 • Understanding the factors associated with DMT adherence may help to identify targets for future patient-centered adherence initiatives.
Methods
• • Cross-sectional • Self-reported (social desirability and recall bias)
• Generalizability to MS patients outside of NARCOMS (high adherence)
Disclosures
• This study was funded by Novartis Pharmaceuticals Corporation.
• Vivian Herrera and Rahul Sasane are employees of Novartis Pharmaceuticals Corporation.
• Andrew Thach and Carolyn Brown received research grants from Novartis Pharmaceuticals Corporation.
• Kenneth Lawson received research funding from Novartis Pharmaceuticals Corporation for a different research project.
• Jamie Barner and Kentya Ford declared no conflict of interest. 
Limitations References
• Most patients were adherent to their current DMT.
• Patients reported high levels of treatment satisfaction and perceived necessity and low levels perceived concern.
• Age, type of DMT and DMT experience were significant predictors of DMT adherence, suggesting that younger patients, those taking injectable DMTs and those who are treatment experienced are at greater risk for nonadherence; as such, these factors should be considered to identify patients who may be at risk for nonadherence. 
Conclusions Study Model Covariates
• Age • Gender • Race • Marital status • Education • Health insurance • Employment status • Time with MS • Type of DMT • Time on DMT • DMT experience Medication Beliefs • Perceived necessity • Perceived concern Treatment Satisfaction • Effectiveness • Side effects • Convenience • Global satisfaction Adherence to DMT
